Sofia\u00ae<\/sup> Q device features a miniaturized, AI-powered design<\/i><\/p>\n Quidel plans initial release to professional and point-of-care segments with a goal of expansion to serve telemedicine and home markets<\/i><\/p>\n SAN DIEGO–(BUSINESS WIRE<\/a>)–Quidel Corporation (NASDAQ: QDEL) (\u201cQuidel\u201d)<\/b>, a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has received an amended Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) allowing the company to market Sofia\u00ae<\/sup> Q,<\/b> its latest addition to the Sofia\u00ae<\/sup> and Sofia\u00ae<\/sup> 2 line of Fluorescent Immunoassay Analyzers (FIA). Sofia Q features a sleek, miniaturized design that reads the same Sofia\u00ae<\/sup> SARS Antigen FIA tests as Sofia and Sofia 2 – with equal accuracy. Sales of Sofia Q device will initially be limited to use with the Sofia\u00ae<\/sup> SARS Antigen FIA in the CLIA and CLIA-waived professional segments.\n<\/p>\n \nSofia Q is the latest product in Quidel\u2019s best-selling Sofia instrumentation portfolio. Sofia Q utilizes Sofia\u00ae<\/sup> fluorescent technology to provide an accurate, objective, and automated result in 15 minutes. Quidel\u2019s innovative design allows the Sofia Q device to be paired with the downloadable Sofia Q mobile application, which guides the user through the workflow and interprets the test result using a proprietary AI model.\n<\/p>\n \n\u201cSofia Q is our latest powerful diagnostic instrument designed to democratize access to the many benefits of our Sofia SARS rapid antigen tests and, ultimately, our full portfolio of Sofia tests for influenza, RSV, Strep and other conditions,\u201d said Douglas Bryant, president and chief executive officer of Quidel Corporation. \u201cWe designed Sofia Q to be very affordably priced and conducive to widespread adoption across the ever-expanding global point-of-care and telemedicine marketplace. In the future, we believe Sofia Q will be ideal to serve consumers at home, as well as in schools and workplaces.\u201d\n<\/p>\n \nIn addition to the Sofia Q, Quidel offers other rapid diagnostic instrumented systems, including Sofia 2, and Sofia. Quidel\u2019s Sofia assays for rapid antigen COVID-19 diagnosis include Sofia\u00ae<\/sup> 2 SARS Antigen FIA and Sofia\u00ae<\/sup> 2 Flu + SARS Antigen FIA, currently under EUA by the FDA. Quidel offers other FDA-cleared and CLIA-waived tests including Influenza A and B, Respiratory Syncytial Virus (RSV), Group A Strep, and a 15-minute finger-stick whole blood test for Lyme Disease. In addition, Quidel also markets Sofia tests for Lyme Disease, Legionella and S. pneumoniae in Europe.\n<\/p>\n About Quidel Corporation<\/b><\/p>\n \nQuidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic solutions at the point of care, delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe. An innovator for over 40 years in the medical device industry, Quidel pioneered the first FDA-cleared point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted brand names Sofia\u00ae<\/sup><\/i> Solana\u00ae<\/sup><\/i>, Lyra\u00ae<\/sup><\/i>, Triage\u00ae<\/sup><\/i> and QuickVue\u00ae<\/sup><\/i>, Quidel\u2019s comprehensive product portfolio includes tests for a wide range of infectious diseases, cardiac and autoimmune biomarkers, as well as a host of products to detect COVID-19. With products made in America, Quidel\u2019s mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the good of our families, our communities and the world. For more information about Quidel, visit quidel.com<\/a>.\n<\/p>\n \nView our story<\/i> told by our people<\/i> at www.quidel.com\/ourstory<\/a>.\n<\/p>\n Forward-Looking Statements<\/b><\/p>\n This press release contains forward-looking statements within the meaning of the federal securities laws that involve material risks, assumptions and uncertainties. Many possible events or factors could affect our future results and performance, such that our actual results and performance may differ materially from those that may be described or implied in the forward-looking statements. As such, no forward-looking statement can be guaranteed. Differences in actual results and performance may arise as a result of a number of factors including, without limitation: the impact and duration of the COVID-19 global pandemic; competition from other providers of diagnostic products; our ability to accurately forecast demand for our products and products in development, including in new market segments; our ability to develop new technologies, products and markets and to commercialize new products; our reliance on sales of our COVID-19 and influenza diagnostic tests; our reliance on a limited number of key distributors; quantity of our product in our distributors\u2019 inventory or distribution channels; changes in the buying patterns of our distributors; the financial soundness of our customers and suppliers; lower than anticipated market penetration of our products; third-party reimbursement policies and potential cost constraints; our ability to meet demand for our products; interruptions, delays or shortages in the supply of raw materials, components and other products and services; failures in our information technology and storage systems; our exposure to data corruption, cyber-based attacks, security breaches and privacy violations; international risks, including but not limited to, economic, political and regulatory risks; continuing worldwide political and social uncertainty; our development, acquisition and protection of proprietary technology rights; intellectual property risks, including but not limited to, infringement litigation; the loss of Emergency Use Authorizations for our COVID-19 products and failures or delays in receipt of reviews or regulatory approvals, clearances or authorizations for new products or related to currently marketed products by the U.S. Food and Drug Administration (the \u201cFDA\u201d) or other regulatory authorities or loss of any previously received regulatory approvals, clearances or authorizations or other adverse actions by regulatory authorities; our contracts with government entities involve future funding, compliance and possible sanctions risks; product defects; changes in government policies and regulations and compliance risks related thereto; our ability to manage our growth strategy and successfully identify, acquire and integrate potential acquisition targets or technologies and our ability to obtain financing; our acquisition of Alere\u2019s Triage\u00ae<\/sup> business presents certain risks to our business and operations; the level of our deferred payment obligations; our exposure to claims and litigation that could result in significant expenses and could ultimately result in an unfavorable outcome for us, including the ongoing litigation between us and Beckman Coulter, Inc.; we may need to raise additional funds to finance our future capital or operating needs; our debt, deferred and contingent payment obligations; competition for and loss of management and key personnel; business risks not covered by insurance; changes in tax rates and exposure to additional tax liabilities or assessments; and provisions in our charter documents and Delaware law that might delay or impede stockholder actions with respect to business combinations or similar transactions. Forward-looking statements typically are identified by the use of terms such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cmight,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201cintend,\u201d \u201cgoal,\u201d \u201cproject,\u201d \u201cstrategy,\u201d \u201cfuture,\u201d and similar words, although some forward-looking statements are expressed differently. The risks described in reports and registration statements that we file with the Securities and Exchange Commission from time to time, should be carefully considered, including those discussed in Item 1A, \u201cRisk Factors\u201d and elsewhere in our Annual Report on Form 10 K for the year ended December 31, 2020 and in our subsequent Quarterly Reports on Form 10 Q. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management\u2019s analysis only as of the date of this press release. Except as required by law, we undertake no obligation to publicly release any revision or update of these forward-looking statements, whether as a result of new information, future events or otherwise.<\/i><\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210611005462\/en\/<\/a><\/span><\/p>\n \nQuidel Contact: \nMedia and Investors Contact: KEYWORDS:<\/b> California United States North America<\/p>\n INDUSTRY KEYWORDS:<\/b> Biotechnology FDA Health Medical Devices<\/p>\n<\/p>\n
\n
Quidel Corporation
\n
Randy Steward
\n
Chief Financial Officer
\n
(858) 552-7931\n<\/p>\n
\n
Quidel Corporation
\n
Ruben Argueta
\n
(858) 646-8023
\n
rargueta@quidel.com<\/a><\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20210611005462\/en\/588971\/3\/Quidel_Horiz_Sml_Vector_CMYK.jpg\")
<\/td>\n<\/tr>\n